DEA in Biden administration thwarted marijuana rescheduling - report
DEA's Resistance to Cannabis Rescheduling: During the Biden administration, DEA officials reportedly resisted efforts to reschedule cannabis from Schedule I to Schedule III, leading to a stalled process and skepticism about the future of cannabis reform.
Impact of Leadership Changes: The proposal to move marijuana to Schedule III was signed by former Attorney General Merrick Garland instead of the DEA Administrator, indicating potential internal conflicts, while supporters believe their chances for rescheduling diminished with Biden leaving office.
Trade with 70% Backtested Accuracy
Analyst Views on MJ
About the author
Canopy Growth Set to Purchase MTL Cannabis
Acquisition Details: Canopy Growth Corporation has agreed to acquire MTL Cannabis Corp. for approximately 125 million Canadian dollars in a cash-and-stock deal, with MTL shareholders receiving shares and cash for their holdings.
Strategic Benefits: The acquisition is expected to enhance Canopy's position in Canada's medical cannabis market, expanding its patient network and improving access to high-quality flower supply, particularly in Québec.
Financial Performance: MTL reported net revenue of 84 million Canadian dollars and a gross margin of 51% as of September 30, 2025, while Canopy anticipates annualized cost synergies of about 10 million Canadian dollars within 18 months.
Management Changes: Following the acquisition, MTL's leadership team will join Canopy Growth, with MTL CEO Michael Perron becoming the Chief Operating Officer, indicating a strategic integration of both companies' operations.
Cannabis ETFs Surge by Double Digits on Friday: Find Out the Reasons
Cannabis Stock Surge: On December 12, 2025, cannabis stocks experienced a significant surge, with the Amplify Seymour Cannabis ETF rising over 54% due to reports of President Trump's plans to reclassify marijuana from Schedule I to Schedule III, which could ease federal regulations and encourage investment.
Potential Reclassification Impact: The reclassification would allow cannabis companies to benefit from different tax regulations and potentially increase pharmaceutical acceptance, although uncertainties remain regarding the final policy confirmation.
Market Reactions: Other cannabis ETFs also saw substantial gains on the same day, including Roundhill Cannabis ETF (up 55.7%) and Advisorshares Pure US Cannabis ETF (up 54.3%), reflecting heightened investor optimism in the sector.
Long-term Industry Outlook: Despite recent gains, the cannabis industry has faced challenges, with stocks like Tilray down significantly over the past five years; however, the current political climate under Trump's second term appears to be more favorable for the industry.
AVGO, the Over-Owned AI Stock, Tops Tech Stock Sales; Marijuana Stocks Gain from Trump Support; NATO Chief Issues Warning
Broadcom Earnings and Stock Performance: Broadcom's earnings exceeded expectations, leading to an initial stock rally; however, a subsequent conference call revealed lower margins, causing a stock decline. The company is considered over-owned and overvalued, primarily relying on revenue from a single customer, Alphabet Inc.
Market Reactions and Trends: The dip in Broadcom's stock has triggered selling across many tech stocks, while aggressive buying from the momentum crowd is noted. Positive seasonality and a dovish stance from Fed Chair Powell have led to increased interest in non-tech stocks and precious metals.
Marijuana Rescheduling Impact: President Trump's plan to reclassify marijuana from Schedule I to Schedule III has resulted in significant gains for marijuana stocks and ETFs, indicating a bullish sentiment in this sector.
Investment Strategies and Market Indicators: Investors are advised to maintain long-term positions while considering protective measures like cash or Treasury bills. A positive short-term market indicator suggests potential opportunities, while traditional 60/40 portfolios may need adjustments to focus on high-quality bonds.
From Decline to Surge: Marijuana ETFs Recover Amid Legalization Hopes
Marijuana ETF Resurgence: Marijuana Exchange-Traded Funds (ETFs) have seen a significant rebound, with some increasing over 100% in the past three months, following a challenging 2024, largely due to renewed optimism from potential U.S. legalization efforts and political support from figures like President Trump.
Market Challenges and Opportunities: Despite a strong demand for cannabis, the market faced heavy losses in 2024 due to regulatory issues, high taxes, and competition from the illicit market; however, recent developments regarding the rescheduling of cannabis have sparked renewed investor interest in various cannabis-focused ETFs.
Cannabis ETFs Light Up As Trump Eyes Cannabis Reclassification
Cannabis Stock Rally: Cannabis stocks and ETFs surged last week after President Trump indicated a potential reclassification of marijuana from Schedule I to Schedule III, which could ease regulations and promote industry growth. Notable gains included Tilray (up 35%) and Trulieve Cannabis (up 35%).
Impact of Reclassification: The proposed reclassification could significantly expand the $30 billion U.S. cannabis market by allowing tax deductions, improving capital access, and reducing federal crackdowns, thereby encouraging more states to consider legalization and enhancing product standards in the medical cannabis sector.
Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification
Cannabis Stock Rally: Cannabis stocks surged following reports that President Trump is considering reclassifying marijuana to a lower danger level, with companies like Canopy Growth and Tilray seeing significant gains.
Reclassification Implications: If marijuana is moved from Schedule I to Schedule III, it could lead to favorable tax regulations and increased investment in the $80 billion market, although the process may take about a year and requires more than just Trump's approval.
Canopy Growth Set to Purchase MTL Cannabis
Acquisition Details: Canopy Growth Corporation has agreed to acquire MTL Cannabis Corp. for approximately 125 million Canadian dollars in a cash-and-stock deal, with MTL shareholders receiving shares and cash for their holdings.
Strategic Benefits: The acquisition is expected to enhance Canopy's position in Canada's medical cannabis market, expanding its patient network and improving access to high-quality flower supply, particularly in Québec.
Financial Performance: MTL reported net revenue of 84 million Canadian dollars and a gross margin of 51% as of September 30, 2025, while Canopy anticipates annualized cost synergies of about 10 million Canadian dollars within 18 months.
Management Changes: Following the acquisition, MTL's leadership team will join Canopy Growth, with MTL CEO Michael Perron becoming the Chief Operating Officer, indicating a strategic integration of both companies' operations.
Cannabis ETFs Surge by Double Digits on Friday: Find Out the Reasons
Cannabis Stock Surge: On December 12, 2025, cannabis stocks experienced a significant surge, with the Amplify Seymour Cannabis ETF rising over 54% due to reports of President Trump's plans to reclassify marijuana from Schedule I to Schedule III, which could ease federal regulations and encourage investment.
Potential Reclassification Impact: The reclassification would allow cannabis companies to benefit from different tax regulations and potentially increase pharmaceutical acceptance, although uncertainties remain regarding the final policy confirmation.
Market Reactions: Other cannabis ETFs also saw substantial gains on the same day, including Roundhill Cannabis ETF (up 55.7%) and Advisorshares Pure US Cannabis ETF (up 54.3%), reflecting heightened investor optimism in the sector.
Long-term Industry Outlook: Despite recent gains, the cannabis industry has faced challenges, with stocks like Tilray down significantly over the past five years; however, the current political climate under Trump's second term appears to be more favorable for the industry.
AVGO, the Over-Owned AI Stock, Tops Tech Stock Sales; Marijuana Stocks Gain from Trump Support; NATO Chief Issues Warning
Broadcom Earnings and Stock Performance: Broadcom's earnings exceeded expectations, leading to an initial stock rally; however, a subsequent conference call revealed lower margins, causing a stock decline. The company is considered over-owned and overvalued, primarily relying on revenue from a single customer, Alphabet Inc.
Market Reactions and Trends: The dip in Broadcom's stock has triggered selling across many tech stocks, while aggressive buying from the momentum crowd is noted. Positive seasonality and a dovish stance from Fed Chair Powell have led to increased interest in non-tech stocks and precious metals.
Marijuana Rescheduling Impact: President Trump's plan to reclassify marijuana from Schedule I to Schedule III has resulted in significant gains for marijuana stocks and ETFs, indicating a bullish sentiment in this sector.
Investment Strategies and Market Indicators: Investors are advised to maintain long-term positions while considering protective measures like cash or Treasury bills. A positive short-term market indicator suggests potential opportunities, while traditional 60/40 portfolios may need adjustments to focus on high-quality bonds.
From Decline to Surge: Marijuana ETFs Recover Amid Legalization Hopes
Marijuana ETF Resurgence: Marijuana Exchange-Traded Funds (ETFs) have seen a significant rebound, with some increasing over 100% in the past three months, following a challenging 2024, largely due to renewed optimism from potential U.S. legalization efforts and political support from figures like President Trump.
Market Challenges and Opportunities: Despite a strong demand for cannabis, the market faced heavy losses in 2024 due to regulatory issues, high taxes, and competition from the illicit market; however, recent developments regarding the rescheduling of cannabis have sparked renewed investor interest in various cannabis-focused ETFs.
Cannabis ETFs Light Up As Trump Eyes Cannabis Reclassification
Cannabis Stock Rally: Cannabis stocks and ETFs surged last week after President Trump indicated a potential reclassification of marijuana from Schedule I to Schedule III, which could ease regulations and promote industry growth. Notable gains included Tilray (up 35%) and Trulieve Cannabis (up 35%).
Impact of Reclassification: The proposed reclassification could significantly expand the $30 billion U.S. cannabis market by allowing tax deductions, improving capital access, and reducing federal crackdowns, thereby encouraging more states to consider legalization and enhancing product standards in the medical cannabis sector.
Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification
Cannabis Stock Rally: Cannabis stocks surged following reports that President Trump is considering reclassifying marijuana to a lower danger level, with companies like Canopy Growth and Tilray seeing significant gains.
Reclassification Implications: If marijuana is moved from Schedule I to Schedule III, it could lead to favorable tax regulations and increased investment in the $80 billion market, although the process may take about a year and requires more than just Trump's approval.
